News, views and contacts from the global Drugdevelopment industry
17 August 2017
Industry News

Iovance commences LN-145 dosing in Phase II trial for cervical cancer
US-based biotechnology firm Iovance Biotherapeutics has commenced patient dosing in its Phase II C-145-04 clinical trial of LN-145 to treat recurrent, metastatic or persistent cervical carcinoma.

Lexicon announces additional positive Phase III data for diabetes drug
Lexicon Pharmaceuticals has reported additional positive data from its Phase III inTandem2 clinical trial of sotagliflozin in adult type 1 diabetes patients on a background of optimised insulin.

Researchers demonstrate use of breast cancer drug to shrink brain tumours
Researchers from the University of Queensland’s Institute for Molecular Bioscience in Australia and the Fred Hutchinson Cancer Research Centre in the US have conducted a clinical trial to evaluate a previously approved breast cancer drug palbociclib to treat brain tumours.

BMS Phase III’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC).

Press Releases

Gamlen Appoints ABL&E as Distributor
Gamlen Instruments has appointed ABL&E as the exclusive distributor for Gamlen Instruments in Eastern Europe.

Powerful Benchtop Spectrometer for Small Spot Analysis
Supplier of analytical X-ray instrumentation and software PANalytical has announced the introduction of a new Epsilon 1 X-ray fluorescence (XRF) spectrometer.

Huge New Opportunity in Generic Drug Development Created by US FDA
The US market is to gain access to previously unavailable therapeutically equivalent generic drug formulations due to a number of changes.

Tailoring the Properties of New Compounds Using XRD Data Analysis
Understanding the make-up of crystalline structures is a vital aspect of the characterisation of new compounds, and can be regarded as an important first step towards the possibility of tailoring its properties.

Upcoming Events Malvern
Malvern will be hosting a wide range of webinars throughout July and August.

White Papers

The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days
The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18...

Softigel by Procaps Brochure
Procaps is one of the world's largest softgel companies, specialising in the production and development of advanced gelatin-related...

Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs
Lack of efficacy is one of the major causes of attrition in the clinical development of new compounds to treat cancer....

Processability Assessment of Crystal Habit-Modified Active Pharmaceutical Ingredients
The efficiency of downstream processing of active pharmaceutical ingredients (API) can depend on their particulate properties, including size and shape....

Validated Metal Analysis
Four commonly utilized carbohydrates for ptotein stabilization are Sucrose, Trehalose, Mannitol, and...

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.